Related Experiment Video
Updated: Apr 13, 2026
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
Chronic obstructive pulmonary disease as a double-edged sword-reshaping NSCLC immunotherapy paradigms
1Department of Medical Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, P.R. China.
None:
Chen et al. demonstrate that NSCLC patients with COPD exhibit superior anti-PD-1 responses through a distinctive immunological mechanism. COPD-driven epithelial remodeling expands CXCL14+ basal-like tumor cells, which orchestrate CXCL9+ macrophage recruitment via CXCL14-CXCR4 signaling, amplifying cytotoxic T cell infiltration.1 This COPD-associated tumor-macrophage axis predicts pathological response and represents both a promising biomarker and potential therapeutic target for refining immunotherapy strategies.
More Related Videos
05:11Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs
Published on: May 10, 2024
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
Related Concept Videos
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...